CD8A and skin disorder: The inhibition of HDAC6 (Class-IIb) with its specific inhibitor (ACY-1215) results in impaired proliferation and activation as well as impaired pro-inflammatory cytokine production of CD8+ T cells during mouse models of skin inflammation, suggesting that HDAC6 represents a key regulator of TCR-signaling and function, therefore might serve as a new drug target for the treatment of CD8+ T cell-related skin disorders (25).